The U.S. Food and Drug Administration has approved Symvess, the first acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent ...

The U.S. Food and Drug Administration (FDA) has officially approved Symvess, the first acellular tissue-engineered vessel designed to repair damaged arteries in extremities. This innovative ...

Pluristyx has developed a clinical-grade manufacturing process for using a licensed Mad7 gene editing technology to block Human Leukocyte Antigen (HLA) markers expression. Humacyte is optimizing a ...

Plans for filing an IND was agreed with the FDA in a recent meeting –– Positive preclinical results of the small-diameter ATEV were recently ...

acellular tissue engineered vessel (sdATEV) in coronary artery bypass grafting (CABG). The Company’s current plans for filing an IND are based on the outcome of a recent meeting held with the ...

Read here for an analysis on Humacyte (HUMA) stock post-Symvess approval, potential upside in revenue generation, and ...

Humacyte’s initial product candidates, a portfolio of acellular tissue engineered vessels (ATEVs), are currently in late-stage clinical trials targeting multiple vascular applications ...

DURHAM, N.C. - Humacyte, Inc. (NASDAQ:HUMA), a biotechnology firm specializing in bioengineered human tissues with a current market capitalization of $580 million, and Pluristyx, Inc., a provider of ...

Humacyte’s Biologics License Application for the acellular tissue engineered vessel (ATEV) in the vascular trauma indication was approved by the FDA in December 2024. ATEVs are also currently in ...

aiming to conduct first-in-human clinical trials of its small-diameter acellular tissue engineered vessel (sdATEV) for coronary artery bypass grafting (CABG). This follows a recent meeting with ...